A bullish thesis on Sotera Health Company was published on Valueinvestorsclub.com by AZA0601, arguing the stock is undervalued. The thesis highlights that Sotera Health, an approximately $6 billion enterprise value provider of sterilization solutions, has seen its valuation compress from ~20x to ~10x EBITDA despite solid fundamentals. Revenue grew from $818 million to $1.16 billion and EBITDA from $420 million to $594 million, with duopoly positions, over 90% multi-year contracts, and high switching costs supporting pricing power and high-50% EBITDA margins. Litigation risk has been de-risked through settlements, and management's 5–7% organic growth guidance is viewed as conservative. At ~12x EBITDA less capex, the valuation points to ~$30 per share versus ~$17.10 as of June 25th, implying a ~25% three-year IRR with further upside from regulation, consolidation, and pricing strength.
Sotera Health CoBullish thesis on Valueinvestorsclub.com argues stock is undervalued with ~25% IRR potential
Danaher Corporation
Sasol Ltd